We report about a case of a compassionate off-label use of the anti-interleukin-5-agent mepolizumab in a ventilated patient with life-threatening asthma attack in eosinophilic asthma. The patient suffered from severe eosinophilic asthma and was transmitted to our hospital with an asthma attack and a life-threatening respiratory state under ventilation. Since high dose steroids had not yielded a sufficient respiratory improvement mepolizumab was administered subcutaneously. After administration of mepolizumab respiratory state and ventilation parameter improved significantly. Two days after administration the patient was weaned could be extubated 8 days later and recovered completely from the asthma attack. The presented clinical case is suggestive of future clinical trials or registry studies to evaluate potential clinical benefits of anti-interleukin-5 treatment in patients with severe exacerbations of eosinophilic asthma.
- Tello, K.
- Hoffmann, A.
- Beutel, B.
- Greulich, T.
- Vogelmeier, C. F.
- Richter, M. J.
- Kuhnert, S.
- Boselt, T.
- Alter, P.
- Holland, A.
- Idzko, M.
- Buhl, R.
- Koczulla, A. R.
Keywords
- Anti-IL-5-therapy
- Asthma
- Eosinophilia
- Exacerbation
- Intensive care medicine
